2023年全國碩士研究生考試考研英語一試題真題(含答案詳解+作文范文)_第1頁
已閱讀1頁,還剩58頁未讀 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

1、絕經(jīng)后激素受體陽性乳腺癌患者高危人群的內(nèi)分泌治療,北京大學人民醫(yī)院王 殊,ER陽性患者預后,EBCTCG,Lancet. 2005,Long-Term Risk of Breast Cancer,Presented By Ian Smith at 2014 ASCO Annual Meeting,Clinical trials,MA17,Anastrozoleletrozoleexemetane,BIG 1-98,ATAC,AB

2、CSG 6a,IES,B 33,ABCSG-8 ARNO95/ITA,TEAM,Upfront switch/sequential extended,MA27,ANA 5Y,EXE 5Y,FACE,ANA 5Y,LET 5Y,Head to head,ATTOM,ATLAS,Tamoxifen,高危人群,腫瘤大小淋巴結(jié)轉(zhuǎn)移組織學分級ER/PRHER2Ki67,分子分型 RS

3、 ROR,淋巴結(jié)轉(zhuǎn)移與生存,,Annals of Oncology, 2007,受體陽性乳腺癌患者的生存(SEER Data),,,,0.95,,1.00,0.90,0.85,0.80,0.75,0,10,20,30,40,50,60,70,80,,,Survival (mo),Cumulative proportion surviving,Joint ER/PR Phenotype,ER+PR+ (n=12,811),ER+PR-

4、 (n=2,436),ER-PR+ (n=663),,,,,,,,,,,,,Node-negative patientswith T1-T3 tumors,HER2陽性患者預后較差,Tamoxifen,Anastrozole,RFS,RFS,Dowsett,JCO,2008,Ki-67,Pathol Oncol Res. 2014,10,21-Gene Recurrence Score Assay forPostmenop

5、ausal, ER(+) Breast Cancer,Lancet Oncol. 2010,,,,,,,,,,,,,高危人群 風險控制,AI還是TAM?初始還是序貫?5年還是更長?,高危人群 風險控制,AI還是TAM?初始還是序貫?5年還是更長?,ATAC,BIG1-98,,Relationship of ER level and response to ET,,,,,,,,,高危人群 風險控制,AI還是TAM?初始還是序貫

6、?5年還是更長?,BIG1-98 序貫,,,,高危人群 風險控制,AI還是TAM?初始還是序貫?5年還是更長?,Pooled analysis ATLAS + aTTom:Breast Cancer Mortality,Presented By Ian Smith at 2014 ASCO Annual Meeting,Extended Adjuvant Therapy with AIs,Presented By Ian Smit

7、h at 2014 ASCO Annual Meeting,Slide 13,Presented By Ian Smith at 2014 ASCO Annual Meeting,Slide 14,Presented By Ian Smith at 2014 ASCO Annual Meeting,Longer-Term Outcomes of Letrozole v. Placebo After 5Years of Tamoxifen

8、 in the MA.17 Trial: Analyses Adjusting for Treatment Crossover,Presented By Ian Smith at 2014 ASCO Annual Meeting,MA17,HR = 0.61,P = .04,Slide 17,Presented By Ian Smith at 2014 ASCO Annual Meeting,,,Slide 19,Presented B

9、y Ian Smith at 2014 ASCO Annual Meeting,Slide 20,Presented By Ian Smith at 2014 ASCO Annual Meeting,Slide 21,Presented By Ian Smith at 2014 ASCO Annual Meeting,How Long Is Long Enough? Defining Optimal Duration and Selec

10、tion of Adjuvant Endocrine Therapy,Presented By Ian Smith at 2014 ASCO Annual Meeting,ConclusionSo What do We Do As Clinicians?,Presented By Ian Smith at 2014 ASCO Annual Meeting,,,,,,,,,,,,,,,,,副作用-ATAC,副作用 BIG1-98,副作用-

11、IES,Value-Based Approach to Systemic Therapy in Patients with Breast Cancer: What is the Evidence?,Presented By Michael Hassett at 2014 ASCO Annual Meeting,What do we get for what we spend?,Presented By Michael Hassett a

12、t 2014 ASCO Annual Meeting,Value?,Presented By Michael Hassett at 2014 ASCO Annual Meeting,Valuable treatments should produce outcomes that reflect meaningful clinical benefit to patients,Presented By Michael Hassett at

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 眾賞文庫僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論